vadadustat + sevelamer carbonate

Vadadustat + sevelamer carbonate is a **combination of two orally administered small-molecule drugs**, typically used together in patients with **chronic kidney disease (CKD) on dialysis**. **Vadadustat** is a hypoxia-inducible factor prolyl hydroxylase inhibitor that increases endogenous erythropoietin production to treat anemia caused by CKD, stimulating red blood cell formation[4][5]. **Sevelamer carbonate** is a non-absorbed polymer phosphate binder, used to lower serum phosphorus by binding dietary phosphate in the gut, thus controlling hyperphosphatemia in CKD patients on dialysis[2][6][7]. Their co-administration is clinically relevant for CKD patients with both anemia and hyperphosphatemia; however, simultaneous administration reduces vadadustat's systemic exposure due to binding interactions, so dosing should be separated by at least 1 hour to avoid pharmacokinetic interactions[1][3][4].